Microcap Ledger Dare Bioscience, Inc. $DARE
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- San Diego, CA
- Fiscal year end
- December 31
- Shares outstanding
- 15,289,502 [10-Q 2026-08-13]
What the company doesAI summary of filing
Dare Bioscience is a clinical-stage bioscience company focused on women's health. The company develops and commercializes products across contraception, sexual health, menopause, vaginal health, and infectious disease. It generates revenue from royalties and milestone payments related to XACIATO (clindamycin phosphate vaginal gel), an FDA-approved bacterial vaginosis treatment licensed to Organon, and from two recently commercialized products: DARE to PLAY, a compounded sildenafil cream for female sexual arousal launched in December 2025, and DARE to RESTORE vaginal probiotic suppositories launching in mid-2026. The company also has multiple product candidates in clinical development, with Ovaprene, a hormone-free monthly intravaginal contraceptive, in a pivotal Phase 3 study. [10-K 2026-03-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $340.0K | −$5.98M | −$12.30M | $12.62M | [10-Q 2026-08-13] |
| FY ended Dec 2025 | $1.03M | −$13.40M | −$9.89M | $24.71M | [10-K 2026-03-26] |
| FY ended Dec 2024 | $9.8K | −$4.05M | $5.47M | $15.70M | [10-K 2026-03-26] |
- Quarterly cash burn
- −$6.15M
- Cash runway Estimate
- ~6.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-13 | 8,700,389 | [10-Q 2024-11-14] |
| 2025-03-28 | 8,850,386 | [10-K 2025-03-31] |
| 2025-05-12 | 8,850,386 | [10-Q 2025-05-13] |
| 2025-08-13 | 13,479,502 | [10-Q 2025-08-14] |
| 2025-11-12 | 14,289,229 | [10-Q 2025-11-13] |
| 2026-03-25 | 14,559,502 | [10-K 2026-03-26] |
| 2026-05-13 | 14,979,502 | [10-Q 2026-05-14] |
| 2026-08-12 | 15,289,502 | [10-Q 2026-08-13] |
- Shelf registration
- S-1 filed 2026-08-26; declared effective 2026-09-03 [S-1 2026-08-26]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-10-02. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-10-02 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-10-02] |
| 2026-07-17 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-07-17] |
| 2025-02-14 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-02-14] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-06-30 | Grossman Jessica D. | grant | 26,066 | — | [4 2026-07-02] |
| 2026-06-30 | Kelley Susan L. | grant | 23,696 | — | [4 2026-07-02] |
| 2026-06-30 | Matz Gregory W | grant | 30,805 | — | [4 2026-07-02] |
| 2026-06-30 | Rastetter William H | grant | 38,862 | — | [4 2026-07-02] |
| 2026-06-30 | Steele Robin Joan | grant | 26,540 | — | [4 2026-07-02] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-06 | DEF 14A | Proxy statement |
| 2026-10-02 | 8-K | Listing notice or transfer |
| 2026-10-01 | 8-K | Regulation FD disclosure |
| 2026-09-23 | PRE 14A | Proxy statement |
| 2026-09-11 | 8-K | Charter, bylaws or fiscal year change |
| 2026-09-09 | 8-K | Regulation FD disclosure |
| 2026-09-04 | 424B3 | Prospectus or prospectus supplement |
| 2026-08-28 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-26 | S-1 | Registration statement |
| 2026-08-24 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-17 | 8-K | Material agreement entered; Unregistered sale of equity; Other events |
| 2026-08-17 | 424B5 | Prospectus or prospectus supplement |
Alerts for $DARE
Email me when Dare Bioscience, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.